RxDoctor Payments Data

Michael Barron, MD

Interventional Cardiology · Sarasota, FLNPI 1912999038

Payments from drug & device makers

$1,844in general payments, 2019–2025

Across 70 payments — averaging $26.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$724
  • Merck$183
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$178
  • Baxter Healthcare$125
  • Amgen$124
  • Boston Scientific$84
  • plus $426 from 11 others

What the payments were for

  • Food & beverage$1,81198%
  • Education$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,844 in reported general payments places this provider in the 15th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$363,589
Medicare patients
1,376
Services billed
4,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban557$701,671
EntrestoSacubitril/Valsartan104$149,115
XareltoRivaroxaban104$130,107
Repatha SureclickEvolocumab152$109,986
MultaqDronedarone Hcl21$32,262
BrilintaTicagrelor30$18,792
FarxigaDapagliflozin Propanediol17$14,492
Praluent PenAlirocumab16$11,686
JardianceEmpagliflozin15$11,629
Metoprolol Succinate732$10,756
Diltiazem 24hr Er (Cd)Diltiazem Hcl255$7,046
Rosuvastatin Calcium433$4,889
Dabigatran EtexilateDabigatran Etexilate Mesylate14$4,663
Losartan Potassium359$3,671
Isosorbide Mononitrate ErIsosorbide Mononitrate172$3,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$701,671557 claims
NovartisEntresto$80$149,115104 claims
Johnson & JohnsonXarelto$33$130,107104 claims
AstraZenecaBrilinta, Farxiga$57$33,28447 claims
Sanofi-aventis U.S. LLCMultaq$24$32,26221 claims
Boehringer IngelheimJardiance$30$11,62915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →